There are two main types of brain cancer. Primary brain cancer starts in the brain. Metastatic brain cancer starts somewhere else in the body and moves to the brain. Brain tumors can be benign, with no cancer cells, or malignant, with cancer cells that grow quickly. Also called glioma, meningioma.
Australian researchers have identified a protein that could protect the kidneys from 'bystander' damage caused by cancer therapies.
Scientists have designed a new targeted therapy, known as POMHEX, which inhibits vital metabolic pathways in tumor cells containing specific genetic defects.
Researchers have shown that the advanced CRISPR/Cas9 system is extremely effective in curing metastatic cancers.
For many cancers, doctors are increasingly looking to the DNA that solid tumors shed into the blood stream to help with diagnosis and monitoring.
Researchers have designed a laboratory test that can precisely examine the deadliest cells found in the most common and aggressive type of brain cancer.
Scientists have identified key molecules that mediate radioresistance in glioblastoma multiforme; these molecules are a potential target for the treatment of this brain cancer.
Interpreting the particular mutations that play a role in different forms of cancer is crucial to enhance diagnosis and treatment.
Australian researchers have discovered that removing copper from the blood can destroy some of the deadliest cancers that are resistant to immunotherapy using models of the disease.
Brain tumors are typically diagnosed using MRI imaging, as taking a sample for a tissue biopsy is risky and may not be possible due to tumor location or a patient's poor health conditions.
More than 200 genes with novel and known roles in glioblastoma - the most aggressive type of brain cancer - offer promising new drug targets.
Rare inherited mutations in the body's master regulator of the DNA repair system – the TP53 gene – can leave people at a higher risk of developing multiple types of cancer over the course of their lives.
Therapies for treating glioblastoma brain cancer can be delivered with greater precision and existing drugs can be used in new ways.
Researchers from IRB Barcelona, the University of Barcelona (UB) and the Sant Joan de Déu Research Institute - Hospital Sant Joan de Déu (SJD) have set up Gate2Brain, a company based on a novel technology developed at IRB Barcelona to transport drugs into the brain.
A highly sensitive blood test has been found to accurately diagnose and classify different types of brain tumors, resulting in more accurate diagnosis.
A novel molecule LIH383 developed by scientists at the Luxembourg Institute of Health binds to and inhibits a formerly unknown opioid receptor in the brain.
In a vertical climb to avoid collision with a towering mountain, a plane ejects cargo to gain altitude. Investigators at the University of Minnesota showed that cancer cells perform similar feats in escaping the killing effects of radiation.
For the past 70 years, the best indicator of life expectancy for a patient with glioblastoma (GBM) -- the most common and the most aggressive brain cancer -- has simply been age at diagnosis.
Dr. Manel Esteller speaks to AZoLifeSciences about his ground-breaking cancer research in which he uncovered the behavior of DNA in 3D models.
A group of researchers has developed a new way to deliver molecules that target specific genes within cells.
A combination of immunotherapy agents that encourages some immune cells to eat cancer cells and alert others to attack tumors put mice with a deadly type of brain cancer called glioblastoma into long-term remission, a new study led by UT Southwestern scientists suggests.